

PALIVIZUMAB
Supporting information

This guideline has been prepared with reference to the following:

North Region Specialised Commissioning Team. Commissioning of Palivizumab - To reduce the risk of RSV in high risk infants for the 2018 vaccination season (letter). 2018

https://www.networks.nhs.uk/nhs-networks/yorkshire-humber-neonatal-odn/guidelines-1/guidelines-new/respiratory/commissioning-of-palivizumab-to-reduce-the-risk-of-rsv-in-high-risk-infants-for-the-2016-vaccination-season/at_download/file

Committee on infectious diseases and bronchiolitis - Guidelines committee. Policy statement: updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415-20

<https://publications.aap.org/pediatrics/article/134/2/e620/32961/Updated-Guidance-for-Palivizumab-Prophylaxis-Among>

Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technology Assessment 2011;15:1-124

<https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0014983/>

Last amended February 2019
Last reviewed December 2021